Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Department of Oncology is pleased to announce that Professor Amato J Giaccia has been appointed as the new Director of the MRC Oxford Institute for Radiation Oncology (OIRO).

Professor Amato Giaccia

Professor Giaccia joins the Department after many successful years as Director of the Division of Radiation & Cancer Biology at the University of Stanford, California.  He is internationally recognised for his contribution to understanding the role of tumour microenvironment, hypoxia, and HIF-1-mediated pathways in cancer.  He has more than 20 years of experience in his field of research with over 200 publications in addition to serving on a number of committees and editorial boards.

His international standing, plus his wealth of experience in the field of radiation oncology will ensure the continued success of OIRO and its close working relationships with cancer collaborators and major funding bodies.  Professor Gavin Screaton, Head of the Medical Sciences Division, commented: ‘Amato is a fantastic catch for the Oxford oncology community and we are delighted he has chosen to join us from Stanford. He has already made his presence felt having hit the ground running and we look forward to him taking the Institute to the next level’.

Professor Mark Middleton, Head of the Department of Oncology, said:   ‘The Department of Oncology is excited that Professor Giaccia has agreed to join us at such a momentous time to help us secure the future of OIRO and the contribution it makes to the world of radiation oncology’.

Dr Mariana Delfino-Machin, MRC Programme Manager for Cancer, said: ‘OIRO is the MRC’s major strategic investment in radiation oncology research and the appointment of Professor Giaccia provides a platform for OIRO to build upon its significant discoveries in the field.  Professor Giaccia is an excellent addition to the UK’s radiation oncology community’.

Similar stories

Machine Learning Predicts SETD2 Mutation Status with Unprecedented Accuracy using DNA methylation

In a pan-cancer analysis spanning 24 different cancer type, researchers shed light on the critical role of SETD2 in tumourigenesis.

Oxford to launch UK’s first trials unit dedicated to conducting precision prevention and early detection studies

Oxford researchers have been given a £1 million boost to support their strategy of developing cancer prevention treatments and early diagnostic tools for people at high risk of cancer.

Multi-cancer blood test shows real promise in NHS trial

An NHS trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5,000 people who had visited their GP with suspected symptoms, in England or Wales. The test also correctly identified the original site of cancer in 85% of those cases.

The Howat Foundation to fund Chair in Clinical Oncology

Oxford Cancer announce the endowment of a Chair in Clinical Oncology, thanks to generous philanthropic support from The Howat Foundation

New Oxford and Nottingham developed tool uses existing health records to predict people’s risk of developing lung cancer within the next 10 years

A team of researchers from the University of Oxford and the University of Nottingham have developed a new tool, called ‘CanPredict’, aimed at identifying the people most at risk of developing lung cancer over the next 10 years, and put them forward for screening tests earlier, saving time, money and, most importantly, lives.

Mark Hill becomes Fellow of the Institute of Physics and Engineering in Medicine

Dr Mark Hill was awarded the honour of Fellow of the Institute of Physics and Engineering in Medicine (FIPEM) after ‘demonstrating scientific and professional attainment of outstanding merit’.